MBX 2109, a once-weekly PTH replacement therapy, shows promising phase 1 results with stable drug concentration ... i.e., it's able to produce the exact benefit a prodrug is supposed to provide. In ...
Nipocalimab was granted U.S. FDA Breakthrough Therapy Designation for the treatment of adults living with moderate-to-severe Sjögren's disease based on results from the Phase 2 DAHLIAS study ...